|
Dear Brony,
Tykerb is going before the next meeting of the
Pharmaceutical Benefits Advisory Committee, which meets from October
31-November 2 (end of this week), to consider (amongst many issues)
whether Tykerb should be listed on the Pharmaceutical Benefits Scheme.
Listing on the PBS would mean subsidised access to the drug for all
eligible women. However if Tykerb is not listed, this should not affect current access to Tykerb through the Tykerb Access Program.
At this stage, GlaxoSmithKline have advised that they will continue
to accept women into the Tykerb Access Program until November 30. Women
in this program will continue to receive Tykerb at no cost. Between
November 30 and March 2008 any women wanting to access Tykerb who are
not currently on the Program can join under a cost sharing arrangement.
Details of this have not yet been released.
So the bottom line is that regardless of whether Tykerb is approved for
listing on the PBS, this should not alter current access to the
drug through the Tykerb Access Program.
Hope this helps,
Adrien
|